Literature DB >> 8020801

Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

R H Hardwick1, N A Shepherd, M Moorghen, P V Newcomb, D Alderson.   

Abstract

Adenocarcinoma arising in Barrett's oesophagus is often preceded by mucosal dysplasia, but little is currently known about the aetiology or natural history of this dysplasia/carcinoma sequence. To investigate the participation of the tumour suppressor gene p53 in this sequence, an immunohistochemical analysis of p53 protein overexpression, which is known to closely correlate with point mutation of the p53 gene, was conducted in 30 patients with Barrett's adenocarcinoma. Adjacent Barrett's mucosa was dysplastic in 21 (70%) patients. Sixteen (53%) tumours overexpressed p53, 10 of which had adjacent dysplastic Barrett's mucosa. In all 10 patients, this dysplastic mucosa also overexpressed p53, predominantly in areas of high grade compared with low grade dysplasia. In contrast, none of the dysplastic mucosa adjacent to 11 tumours lacking p53 overexpression showed detectable values of p53. These results suggest that p53 dysfunction may participate in the progression from dysplasia to carcinoma in some patients with Barrett's oesophagus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020801      PMCID: PMC1374874          DOI: 10.1136/gut.35.6.764

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  52 in total

1.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium.

Authors:  A J Cameron; C T Lomboy
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

2.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

Review 3.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

4.  Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.

Authors:  S Ramel; B J Reid; C A Sanchez; P L Blount; D S Levine; K Neshat; R C Haggitt; P J Dean; K Thor; P S Rabinovitch
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

5.  High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx.

Authors:  R Maestro; R Dolcetti; D Gasparotto; C Doglioni; S Pelucchi; L Barzan; E Grandi; M Boiocchi
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

Review 6.  The neoplastic potential of columnar-lined (Barrett's) esophagus.

Authors:  G N Tytgat; W Hameeteman
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  High levels of p53 protein in UV-irradiated normal human skin.

Authors:  P A Hall; P H McKee; H D Menage; R Dover; D P Lane
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  p53 expression in colorectal adenomas.

Authors:  L Kaklamanis; K C Gatter; N Mortensen; R J Baigrie; A Heryet; D P Lane; A L Harris
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

10.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

Authors:  C A Midgley; C J Fisher; J Bártek; B Vojtĕsek; D Lane; D M Barnes
Journal:  J Cell Sci       Date:  1992-01       Impact factor: 5.285

View more
  13 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Current status of gene therapy in gastroenterology.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

3.  Gene therapy in gastroenterology.

Authors:  H S Pandha; N R Lemoine
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

Review 4.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

5.  Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.

Authors:  R Kim; M R Clarke; M F Melhem; M A Young; M M Vanbibber; A V Safatle-Ribeiro; U Ribeiro; J C Reynolds
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

Review 6.  Barrett's esophagus. The significance of p53 in clinical practice.

Authors:  A P Ireland; G W Clark; T R DeMeester
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

7.  p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia.

Authors:  M Younes; A Ertan; L V Lechago; J R Somoano; J Lechago
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

8.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

10.  Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Authors:  Stephanie J Gros; Nina Kurschat; Astrid Drenckhan; Thorsten Dohrmann; Evelyn Forberich; Katharina Effenberger; Uta Reichelt; Robert M Hoffman; Klaus Pantel; Jussuf T Kaifi; Jakob R Izbicki
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.